Valby, 25 June 2018 Lu AF28996 is the third compound added to Lundbeck's clinical development pipeline in 2018. H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson's disease.

New clinical phase III data from a study conducted in Japan demonstrate the efficacy of vortioxetine compared to placebo for the treatment of Major Depressive Disorder (MDD) in Japanese adults Positive results suggest that vortioxetine may be a potential treatment option for Japanese patients with

Valby, Danmark, 6. juni 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at selskabets amerikanske datterselskab, Lundbeck LLC, har indgået en aftale med det amerikanske Justitsministerium (U.S. Department of Justice (DOJ)) om principperne for en afslutning af myndighedernes undersøgelse

Valby, Denmark, 6 June 2018  - H. Lundbeck A/S (Lundbeck) today announced that its U.S. subsidiary Lundbeck LLC has reached an agreement in principle to resolve the U.S. Department of Justice (DOJ) investigation related to Lundbeck LLC's relationship with and donations to independent patient

Valby, Denmark, 23 May 2018 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 209,730 as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or

Valby, Danmark, 23. maj 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK 209.730 som følge af udnyttelsen af medarbejder-warrants. Kapitalforhøjelsen tegnes uden fortegningsret for selskabets eksisterende aktionærer eller andre.

Pressemeddelelse Valby den 22. maj 2018                                                 To projekter uden for Lundbecks fokusområder overdrages til MindImmune Therapeutics, Inc. H. Lundbeck A/S (Lundbeck) fokuserer nu sin portefølje af prækliniske forskningsprojekter yderligere med frasalget af to

Press release Valby, 22 May 2018 Two programs outside Lundbeck's areas of focus are transferred to MindImmune Therapeutics, Inc. H. Lundbeck A/S (Lundbeck) further focuses its preclinical research pipeline with the divestment of two research programs to biotech company MindImmune Therapeutics, Inc.

Pressemeddelelse Valby den 18. maj 2018                                                 Påbegynder første fase af kliniske undersøgelser af potentiel ny behandling af skizofreni og Alzheimers sygdom. H. Lundbeck A/S (Lundbeck) påbegynder nu den kliniske udvikling af en potentiel ny behandling af